Work

The extinguish trial: A phase-2B randomized placebo-controlled trial of inebilizumab in anti-NMDA receptor encephalitis

Year: 2023

Type: article

Source: Journal of the Neurological Sciences

DOI: 10.1016/j.jns.2023.121236

Authors: Ka-Ho Wong, Gregory Day, James Torner, Merit Cudkowicz, Christopher Coffey, Sophie Cho, Ursula Utz, Eric Klawiter, J. Singleton, Dana Mitchell, Susannah Cahalan, Janel Fedler, Dixie Ecklund, David Klements, Michele Costigan, Brenda Pearson, Erin Steinhart, Christina Desir, Maarten Titulaer, Stacey Clardy

Institutions: University of Utah, Mayo Clinic in Florida, University of Iowa, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke, Erasmus MC

Language: English

Topic: Autoimmune Neurological Disorders and Treatments

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4390262000

FWCI:

Cites:

Cited by:

Related to: 10